Publications

Publications

Publications

A full list of of my publications can be found here: 

https://www.ncbi.nlm.nih.gov/sites/myncbi/1r9Zwxd-aq6QW/bibliography/public/

Pending Publications

  1. Papadopoulos E, Walkow S, Abrimian A, Knapp CP, Loweth JA, Waterhouse BD, Navarra RL. Low dose methylphenidate counteracts increased risky decision making following repetitive mild traumatic brain injury in female rodents. (currently IN REVISION at International Journal of Neuropsychopharmacology)
  2. Papadopoulos E, Abrimian A, Knapp CP, Loweth JA, Waterhouse BD, Navarra RL. Low dose methylphenidate counteracts increased risky decision making following repetitive mild traumatic brain injury in female rodents. (currently IN REVISION at Experimental Neurology)
  3. Navarra RL, Knapp CP, Fallon B, Fox DP, Floresco SB, Raghupathi R, Waterhouse BD. Time course of deficit and recovery following repetitive traumatic brain injury in a rodent assay of cognitive flexibility. (in preparation Journal of Neurotrauma Q4 2025)
  4. Navarra RL, Knapp CP, Kuponiyi OG, Floresco SB, Waterhouse BD.  Methylphenidate enhances specific dimensions of cognitive performance in a rodent strategy shifting assay of cognitive flexibility. (in preparation Neuropsychopharmacology Q4 2025)

Published Original Articles

  1. Knapp CP, Fallon B, Kortagere S, Waterhouse BD, Floresco SB, Navarra RL. SK609, a novel dopamine D3 receptor agonist and norepinephrine transporter blocker with pro-cognitive actions, does not induce psychostimulant-like increases in risky choice during probabilistic discounting. Psychopharmacology. (Accepted November 25, 2024)
  2. Knapp CP, Papadopoulos E, Loweth JA, Raghupathi R, Floresco SB, Waterhouse BD, Navarra RL. Sex-dependent perturbations in risky choice behavior and prefrontal tyrosine hydroxylase levels induced by repetitive mild traumatic brain injury. Behavioural Brain Research. 5:476:115244, 2025. (Accepted September 3, 2024)
  3. Knapp CP, Papadopoulos E, Loweth JA, Raghupathi R, Floresco SB, Waterhouse BD, Navarra RL. Perturbations in risk/reward decision making and frontal cortical catecholamine regulation induced by mild traumatic brain injury. Behavioural Brain Research. 5:467:115002, 2024. (Accepted April 14, 2024)
  4. Navarra RL, Clark BD, Garguilo AT, Waterhouse BD. Methylphenidate enhances early stage sensory processing and rodent performance of a visual signal detection task. Neuropsychopharmacology. 42(6):1326-1337, 2017.
  5. Navarra RL, Clark BD, Zitnik GA, Waterhouse BD. Methylphenidate and atomoxetine enhance sensory-evoked neuronal activity in the visual thalamus of male rats. Exp Clin Psychopharmacol. 21(5):363-374, 2013.
  6. Malamas MS, Stange H, Schindler R, Lankau HJ, Grunwald C, Langen B, Egerland U, Hage T, Ni Y, Erdei J, Fan KY, Parris K, Marquis KL, Grauer S, Brennan J, Navarra R, Graf R, Harrison BL, Robichaud A, Kronbach T, Pangalos MN, Brandon NJ, Hoefgen N. Novel triazines as potent and selective phosphodiesterase 10A inhibitors. Bioorg Med Chem Lett. 22(18):5876-84, 2012.
  7. Malamas MS, Ni Y, Erdei J, Stange H, Schindler R, Lankau HJ, Grunwald C, Fan KY, Parris K, Langen B, Egerland U, Hage T, Marquis KL, Grauer S, Brennan J, Navarra R, Graf R, Harrison BL, Robichaud A, Kronbach T, Pangalos MN, Hoefgen N, Brandon NJ.  Highly potent, selective, and orally active phosphodiesterase 10A inhibitors. J Med Chem. 54(21):7621-38, 2011.
  8. Marquis KL, Comery TA, Jow F, Navarra RL, Grauer SM, Pulicicchio C, Kelley C, Brennan JA, Roncarati R, Scali C, Haydar S, Ghiron C, Terstappen GC, Dunlop J. Preclinical assessment of adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. Psychopharmacology, 218(4):635-47, 2011. 
  9. Kelly MP, Logue SF, Brennan J, Lakkaraju S, Jiang L, Rizzo S, Platt BJ, Dwyer JM, Neal S, Pulito VL, Agostino MJ, Grauer S, Navarra RL, Kelley C, Comery TA, Marquis K, Murrills RJ, Brandon NJ.  PDE11A expression in the brain is enriched in ventral hippocampus and deletion results in schizophrenia-releated phenotypes. PNAS, 107(18):8457-62, 2010.
  10. Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH and Marquis KL (2009) WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist / serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity. Journal of Pharmacology and Experimental Therapeutics, 332(1): 190-201, 2010.
  11. Rotella DP, McFarlane GR, Greenfield A, Grosanu C, Robichaud AJ, Denny RA, Feenstra RW, Núñez-García S, Reinders JH, Neut M, McCreary A, Kruse CG, Sullivan K, Pruthi F, Lai M, Zhang J, Kowal DM, Carrick T, Grauer SM, Navarra RL, Graf R, Brennan J, Marquis KL, Pausch MH. Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia. Bioorganic & Medicinal Chemistry Letters, 19(19):5552-5, 2009.
  12. Grauer SM, Pulito VL, Navarra R, Kelly M, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis K, Malamas M, Hage T, Comery TA, Brandon NJ. PDE10A Inhibitors show anti-psychotic, pro-cognitive and negative symptom activities suggesting broad-spectrum utility for the treatment of schizophrenia. Journal of Pharmacology and Experimental Therapeutics, 331(2):574-590, 2009.
  13. Grauer SM, Graf R, Navarra R, Sung A. Logue SF, Stack G, Huselton C, Liu Z, Comery TA, Marquis KL, Rosenzweig-Lipson S. WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics. Psychopharmacology, 204(1):37-48, 2009.
  14. Liu F, Grauer S, Kelley, C, Navarra R, Graf R, Zhang G, Day M, Gilbert A, Brandon N, Rosenzweig-Lipson S, Marquis K.  ADX-47273: A novel metabotropic glutamate receptor 5 selective positive allosteric modulator has preclinical antipsychotic-like and pro-cognitive activities. Journal of Pharmacolology and Experimental Therapeutics, 327(3):827-39, 2008.
  15. Liu F, Day M, Muniz L, Bitran D, Revilla-Sanchez R, Grauer S, Sung A, Navarra R, Reinhart P, Marquis K, Moss S, Pangalos M, Brandon N. Activation of estrogen receptor beta regulates hippocampus synaptic plasticity and improves memory. Nature Neuroscience, 11(3):334-43, 2008.
  16. Navarra R, Comery TA, Graf R, Rosenzweig-Lipson S, Day M. 5-HT2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test. Behavioural Brain Research: 188(2):412-5, 2008.
  17. Navarra R, Graf R, Huang Y, Logue S, Comery T, Day M. Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test. Progress in Neuro-pharmacology & Biological Psychiatry, 32(1):334-41, 2008.
  18. Day M, Pan, JB, Buckley MJ, Cronin E, Hollingsworth PR, Hirst WD, Navarra R, Sullivan JP, Decker MW, Fox GB. Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochemical Pharmacology, 73(8)1123-34, 2007.

Reviews and Editorials

  1. Waterhouse BD and Navarra RL. The locus coeruleus-norepinephrine system and sensory signal processing: A historical review and current perspectives. Review. Brain Research Special Edition. 1709: 1-15, 2019.
  2. Navarra RL and Waterhouse BD. Considering noradrenergically mediated facilitation of sensory signal processing as a component of psychostimulant-induced performance enhancement. Review. Brain Research Special Edition. 1709: 67-80, 2019.
  3. Navarra RL and Waterhouse BD. “What have we GANEd?” Application of a theoretical construct to explain experimental evidence for noradrenergic regulation of signal processing in sensory networks. – An invited commentary on “Norepinephrine ignites local hot spots of neuronal excitation: How arousal amplifies selectivity in perception and memory. Beh Brain Sciences. E219, 2016.

Journal Special Editions

  1. Waterhouse BD and Navarra RL (editors). Behavioral consequences of noradrenergic actions in sensory networks. Brain Research Special Edition. 1709: 1-15, 2019.